Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit

BACKGROUND: The treatment effect in survival analysis is commonly quantified as the hazard ratio, and tested statistically using the standard log-rank test. Modern anticancer immunotherapies are successful in a proportion of patients who remain alive even after a long-term follow-up. This new phenom...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Natl Cancer Inst
Päätekijät: Péron, Julien, Lambert, Alexandre, Munier, Stephane, Ozenne, Brice, Giai, Joris, Roy, Pascal, Dalle, Stéphane, Machingura, Abigirl, Maucort-Boulch, Delphine, Buyse, Marc
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6855951/
https://ncbi.nlm.nih.gov/pubmed/30838402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djz030
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia